Who are the leading contract research organizat… | Parse
Who are the leading contract research organizations for running oncology clinical trials in Eastern Europe?
Data as of Sep 26, 2026 · Based on 290 AI responses from ChatGPT Search and Google AI Mode · See how Parse measures this
For running oncology clinical trials in Eastern Europe, firms like HungaroTrial, Cromos Pharma, and OCT Clinical are frequently recommended for their regional expertise and speed in patient enrollment. Global CROs such as IQVIA, ICON, and are also strong contenders for when the trial requires larger operational scale or multisite coordination across global and regional networks.
Preferred for deep regional expertise in Eastern Europe and the CIS, specifically in identifying difficult-to-recruit patient populations across major solid tumor cancers.
Best for sponsors seeking rapid study start-up and specialized patient recruitment networks specifically across Central and Eastern Europe for various oncology trial phases.
The Leading CRO in Eastern Europehttps://oct-clinicaltrials.com/about-oct-clinical
8%
HungaroTrial - Homehttps://hungarotrial.com/
5%
List of European Contract Research Organizations (CRO) for ...https://www.sofpromed.com/list-of-european-contract-research-organizations-cro-for-clinical-trials-part-2
4%
European CRO for Oncology Clinical Trials in the EU - Sofpromedhttps://www.sofpromed.com/european-cro-for-oncology-clinical-trials-in-the-eu
4%
Accell Clinical Research - Clinical Trials in Europehttps://accellclinical.com/
4%
OCT Clinical CRO — Managing Clinical Trials in Eastern Europehttps://oct-clinicaltrials.com/
4%
European CRO Services | Precision for Medicinehttps://www.precisionformedicine.com/clinical-trial-services/europe
3%
Cromos Pharma | Contract Research Organization (CRO)https://cromospharma.com/
3%
Top 10 CROs to Watch in 2025 - Proclinicalhttps://www.proclinical.com/blogs/2025-3/top-10-cros-to-watch-in-2025
3%
Top Clinical Research Organizations for Oncology in 2024https://www.precisionformedicine.com/blog/top-oncology-cros-in-2024-and-beyond
3%
Question: Who are the leading contract research organizations for running oncology clinical trials in Eastern Europe?
If by “leading” you mean CROs with substantial Eastern/Central European infrastructure plus demonstrated oncology experience, I’d put the following firms on a sponsor’s shortlist. This isn’t a ranking; the right choice depends heavily on countries, phase, tumor type, recruitment target, and whether you need a full-service CRO or regional execution partner.
CRO
Eastern European footprint
Oncology relevance
Particularly useful for
HungaroTrial
Poland, Hungary, Czech Republic, Romania, Bulgaria, Serbia, Slovakia, Croatia, Bosnia, N. Macedonia and others
Broad Phase I–IV experience; oncology is among its established therapeutic areas
Regional CEE trials, particularly when you want one locally embedded CRO across several countries
75+ studies across 15+ therapeutic areas; extensive regional PI/site network
CEE recruitment and site management, especially multi-country EU studies
Precision for Medicine
Hungary, Poland, Romania, Slovakia, Serbia, through its CEE operations
Global oncology/biopharma CRO capabilities combined with CEE infrastructure
Complex/global oncology programs where you want regional execution plus global CRO capabilities
Cromos Pharma
Broad international network with substantial CEE experience
Explicit oncology CRO offering; has run oncology studies in Poland, Czech Republic, Hungary, Bulgaria and Slovakia
Oncology-focused multinational trials and recruitment optimization
OCT / Palleos
Historically strong Eastern European footprint
OCT reports 300+ Eastern European trials and explicit oncology expertise; OCT has since merged with Palleos
Eastern European regional expertise and oncology programs
FGK Clinical Research
Poland, Czech Republic, Slovakia, Hungary
Primarily Phase II–IV operations, regulatory, monitoring and project management
Phase II–IV European studies, especially when local regulatory/monitoring expertise is important
The ones I'd investigate first
HungaroTrial is particularly notable if your trial is genuinely regional. It describes itself as a CEE-focused CRO with local offices across much of the region and reports more than 380 CEE clinical trials and 15,200 enrolled patients.
Cromos Pharma deserves a closer look for an oncology-specific program. Its published oncology case study involved 39 months of enrollment across Poland, Czech Republic, Hungary, Bulgaria and Slovakia, with 392 patients recruited in those five countries.
Precision for Medicine is interesting when you don't necessarily want a purely regional CRO. Its acquisition of Argint gave it a CEE presence spanning Hungary, Poland, Romania, Slovakia and Serbia, alongside its broader global clinical-development infrastructure.
RP-CRO is another credible regional option, particularly where recruitment and local PI relationships are central. It reports operations in Hungary, Poland, Czechia, Romania and Bulgaria, with more than 150 CRO staff and experience across 15+ therapeutic areas.
Why Eastern Europe is particularly relevant for oncology
Poland and Czechia are especially important recruitment markets. A 2025 Cancer Drug Development Forum analysis counted approximately 436 cancer trials recruiting or not yet recruiting in Poland, 227 in Czechia, 175 in Hungary, and 132 in Romania, based on ClinicalTrials.gov data through June 30, 2025.
That means I would evaluate a CRO less on its claimed geographic coverage and more on its actual oncology site network in the specific countries/tumor indications you need.
For an oncology RFP, I'd ask each CRO for:
Recent oncology enrollment performance by country and tumor type
Number of active oncology investigators/sites, rather than total sites in its database
Historical screen-failure and enrollment rates
Feasibility data for your exact inclusion/exclusion criteria
Experience with biomarker-selected patients, central pathology and molecular testing
Experience with Phase I/II vs Phase III, depending on your program
Regulatory/start-up timelines in Poland, Czechia, Hungary, Romania, Bulgaria, etc.
Patient retention and protocol-deviation rates
Oncology medical-monitoring capabilities
References from sponsors running comparable oncology trials
One important distinction: Eastern Europe isn't a single homogeneous clinical-trial market. Poland, Czechia, Hungary and Romania have particularly substantial oncology-trial activity, while the optimal CRO/site mix can change considerably by tumor type and phase.
If you tell me the tumor type, phase (I/II/III), approximate patient count, and which Eastern European countries you're considering, I can narrow this to a 5–7 CRO shortlist and compare their oncology capabilities, footprint, recruitment evidence, and likely fit for your trial.
Precision for Medicine is interesting when you don't necessarily want a purely regional CRO. Its acquisition of Argint gave it a CEE presence spanning Hungary, Poland, Romania, Slovakia and Serbia, alongside its broader global clinical-development infrastructure.
RP-CRO is another credible regional option, particularly where recruitment and local PI relationships are central. It reports operations in Hungary, Poland, Czechia, Romania and Bulgaria, with more than 150 CRO staff and experience across 15+ therapeutic areas.
Why Eastern Europe is particularly relevant for oncology
Poland and Czechia are especially important recruitment markets. A 2025 Cancer Drug Development Forum analysis counted approximately 436 cancer trials recruiting or not yet recruiting in Poland, 227 in Czechia, 175 in Hungary, and 132 in Romania, based on ClinicalTrials.gov data through June 30, 2025.
Running oncology clinical trials in Central and Eastern Europe (CEE) and the Commonwealth of Independent States (CIS) offers distinct advantages, including large treatment-naive patient pools, highly skilled medical staff, and active regional research networks.
Leading contract research organizations (CROs) specializing in or heavily operational in Eastern Europe for oncology studies include the following:
OCT Clinical – Recognized as a top regional CRO with deep roots across Eastern Europe, covering both the CEE and CIS regions. They maintain core therapeutic expertise in oncology alongside a full suite of clinical development services.
Precision for Medicine (via Argint International acquisition) – Following its strategic acquisition of Argint International, Precision built a powerful footprint across Central and South-Eastern Europe (including Poland, Hungary, Romania, Serbia, and Slovakia) tailored to accelerating oncology and specialty patient recruitment.
Pharmaxi LLC – An Eastern European regional CRO conducting clinical trials across Poland, the Czech Republic, Ukraine, and neighboring countries with active operational capabilities spanning oncology, cardiology, and rare diseases.
Clinical Trials Group (CTG) – A reliable regional CRO specializing in clinical study execution and site management with core operations anchored in Eastern Europe and Romania.
Global/Transnational CROs with Heavy Regional Infrastructure – Major global players like IQVIA, PPD (Thermo Fisher Scientific) , and Parexel also manage extensive oncology operations in the region due to large clinical trial hubs established in countries like Poland, the Czechia, and Hungary.
If you'd like to narrow this down, please let me know:
Are you looking for boutique regional CROs or large global players with local offices?
Which specific countries (e.g., Poland, Czech Republic, Baltic states, or CIS region) are you targeting?
When running oncology clinical trials in Eastern Europe (including Central and Eastern Europe/CEE and surrounding regions), sponsors generally choose between major global tier-1 contract research organizations (CROs) with robust regional footprints and specialized regional/boutique CROs that offer deep local site access and rapid recruitment.
The leading contract research organizations operating in this space include:
IQVIA — A massive global leader providing extensive data-driven oncology capabilities and established site networks across Eastern Europe.
ICON plc — Has a significant international infrastructure capable of managing large, complex, late-stage global and regional oncology trials in the CEE region.
PPD (part of Thermo Fisher Scientific) — Features strong hematology/oncology teams and broad geographic reach, frequently contracted for major multi-center international trials.
Parexel — Widely recognized for full-service clinical development from Phase I to IV, with specialized precision oncology frameworks scaling into Europe.
OCT Clinical Trials — A prominent regional specialist explicitly focused on Eastern Europe and CIS countries, recognized for high patient recruitment rates and extensive oncology trial experience.
Pharmaxi LLC — A regional CRO conducting trials across Poland, the Czech Republic, Ukraine, and neighboring Eastern European areas with active portfolios in oncology.
Medpace — A full-service mid-to-large global CRO with a strong medical-driven operational model and robust oncology footprint across Europe.
Would you like to narrow this down based on:
Phase of development (Phase I vs. late-stage Phase III)
Specific country focus (e.g., Poland, Czech Republic, the Baltics)
If you mean CROs with meaningful operational capability in Central/Eastern Europe (CEE) and a track record in oncology, I’d put the following firms on the shortlist. There isn’t a single authoritative “top CRO” ranking, so I’m separating large global CROs from CEE-focused specialists rather than ranking them.
Major global CROs with strong CEE coverage
IQVIA — One of the most active CROs in European oncology. In a 2024–2026 analysis of 887 European Phase III oncology trials, IQVIA appeared in 163 trials, the highest count in that dataset. Trial AgentsTrial Agents It has established operations in countries such as Poland and the Czech Republic.
ICON / PRA — Another major oncology player, appearing in 127 of the same 887 European Phase III oncology trials. ICON has established CEE infrastructure, including the Czech Republic.
PPD, part of Thermo Fisher Scientific — Particularly relevant for large multinational Phase II/III programs. It appeared in 121 European Phase III oncology trials in the 2024–2026 analysis and has a Czech operation.
Parexel — Another large global CRO with extensive CEE capabilities; it appeared in 118 European Phase III oncology trials in the same analysis and has a Czech operation.
Medpace — Worth considering for oncology programs where a more therapeutically focused operating model is desirable. It has an established Czech presence.
PSI CRO — A major international CRO with a particularly strong European footprint and oncology expertise; PSI is also represented in the Czech CRO association.
CEE-focused CROs
HungaroTrial — One of the more established regional specialists. It reports 380+ clinical trials across CEE, 20+ countries and 15,200 enrolled patients, with operations spanning Poland, Hungary, Romania, Czechia, Bulgaria, Serbia, Slovakia, Croatia and other CEE markets.
OCT Clinical — Particularly relevant if you want a CRO built around Eastern European execution rather than simply a global CRO with regional offices. OCT reports 300+ trials since 2005, operations in 21 countries including Poland, Romania, Hungary, Czech Republic, Bulgaria, Serbia, Croatia and Moldova, and 65+ oncology trials.
Accell Clinical Research / Accell Oncology — A regional CRO specifically positioning itself around oncology studies in Eastern Europe and former CIS markets. It reports substantial in-house oncology expertise and experience with Phase III oncology studies.
How I'd structure an RFP shortlist
For a multinational oncology Phase II/III trial, I'd consider a mix such as:
Therapeutic expertise and close operational oversight matter
CEE specialist
, OCT Clinical
The country footprint matters as much as the CRO name. Poland is especially important for oncology research in the region; a recent review describes CEE as an active cancer-research hub and specifically identifies Poland as a model for a productive clinical-trial ecosystem.
If you're actually selecting a CRO for a specific oncology program, I can also build a more useful shortlist comparing IQVIA vs ICON vs PPD vs Parexel vs Medpace vs PSI vs HungaroTrial vs OCT on Poland/Romania/Czechia/Hungary site access, oncology patient recruitment, Phase I–III experience, regulatory capability, typical study scale, and likely fit for your indication.
Yes. If you mean CROs with a meaningful track record of executing oncology trials across Central and Eastern Europe (CEE)—rather than simply global CROs that have an office there—I would put the following group at the top of the shortlist.
Leading choices
IQVIA — probably the strongest overall choice for a large, multinational oncology program. In a recent analysis of 887 European oncology Phase III trials (2024–2026), IQVIA was the most frequently identified CRO, appearing in 163 trials. Trial Agents It has established operations in countries such as Czechia and Poland and can provide the infrastructure for large multinational studies.
ICON / PRA — another top-tier choice for complex multinational oncology studies. It ranked second in the same European oncology Phase III analysis, with 127 trial appearances. Trial Agents ICON also has an established Czech operation.
Medpace — particularly interesting if oncology/hematology depth plus strong CEE site relationships are priorities. Medpace specifically describes flagship-site programs in Poland and Czech Republic, including relationships with academic and public hospitals experienced in hematology and oncology. Medpace Corporate Its broader European operation covers 27 countries.
Parexel — a strong option for global oncology programs requiring substantial regulatory, operational and patient-recruitment infrastructure. It was among the five most frequently appearing providers in the recent European oncology Phase III analysis, with 118 trials. Trial Agents It also has a Czech operation.
PPD / Thermo Fisher Scientific — another major multinational option, appearing in 121 of the European oncology Phase III trials in the recent analysis. Trial Agents Its CEE presence includes Czechia.
PSI CRO — worth serious consideration when you want a smaller, oncology-focused CRO rather than the biggest global platform. PSI has a Czech operation and is active in CEE.
HungaroTrial — probably one of the most interesting regional CEE specialists. It describes itself as a CEE-focused CRO with 380+ trials, 20+ countries and 15,200 enrolled patients, with operations spanning Poland, Czech Republic, Hungary, Romania, Bulgaria, Serbia, Croatia, Slovakia and other regional markets. HungaroTrialHungaroTrial This could be particularly attractive for a sponsor whose trial is heavily weighted toward CEE rather than requiring a huge global CRO footprint.
Research Professionals (RP-CRO) — another strong regional alternative, headquartered in Hungary with operations in Poland, Czechia, Romania and Bulgaria. It reports 150+ CRO staff and experience across 75+ studies and 15+ therapeutic areas.
How I'd narrow it down
For an oncology Phase II/III trial primarily recruiting in Eastern Europe, my initial RFP shortlist would probably be:
CRO
Best fit
IQVIA
Large multinational Phase II/III; maximum infrastructure
ICON
Complex global oncology program
Medpace
Oncology/hematology + strong CEE site relationships
Parexel
Large multinational + regulatory complexity
There is a good underlying reason to focus on CEE: Poland, Czechia, Hungary and Romania are among the region's most important oncology-trial markets. A 2025 analysis of CEE clinical research counted roughly 436 cancer trials in Poland, 227 in Czechia, 175 in Hungary and 132 in Romania that were recruiting or not yet recruiting.
One important distinction
I wouldn't choose solely on "number of trials." For oncology in CEE, I'd ask each CRO for country-level evidence on:
oncology trials completed in the last 3–5 years;
patients randomized per site per month by tumor type;
number of active oncology sites in Poland, Czechia, Hungary, Romania, Bulgaria, Serbia, Croatia, etc.;
median site activation time and first-patient-in time;
experience with biomarker-selected populations and central laboratories;
experience with immuno-oncology, ADCs, bispecifics or cell/gene therapy if relevant;
oncology KOL/site relationships;
historical screen-failure and dropout rates;
regulatory/ethics submission timelines;
proportion of monitoring performed by their own employees versus subcontractors.
That last point can make a surprisingly large difference between a CRO that has offices in Eastern Europe and one that can actually recruit oncology patients there quickly.
If you tell me the tumor type, phase, approximate number of patients/sites, and which Eastern European countries you want to include, I can rank these CROs specifically for your trial and produce a shortlist of 3–5 with a side-by-side assessment of oncology experience, CEE footprint, likely strengths/weaknesses, and relevant evidence of recent trials.
When running oncology clinical trials in Central and Eastern Europe (CEE) and the Commonwealth of Independent States (CIS), sponsors typically choose between specialized regional/mid-sized CROs with deep local site networks and large global giants with heavy local footprints. Eastern Europe is a high-value region for oncology trials due to large patient populations, treatment-naive cohorts, and high-performing clinical trial sites.
The leading contract research organizations operating and specializing in this region include:
OCT Clinical Trials : A prominent regional leader explicitly focused on Eastern Europe, Central Eastern Europe (CEE), and the CIS countries. They manage Phase I-IV trials with a deeply embedded local footprint, extensive regulatory know-how, and core therapeutic strength in oncology.
KCR (now part of ICON) : Historically one of Central and Eastern Europe’s most successful independent regional CRO powerhouses, KCR built its reputation on managing trials across Poland, Ukraine, and wider Eastern Europe. Following its acquisition by ICON , its deep CEE operational infrastructure continues to deliver robust oncology and rare disease trial execution.
Pharmaxi LLC : An agile Eastern European CRO conducting clinical operations across Poland, the Czech Republic, Ukraine, and neighboring countries. They manage full-service clinical trials across multiple indications, including a dedicated track record in oncology for mid-to-large pharmaceutical developers.
Cromsource : A prominent international mid-sized CRO with a powerful, long-standing operational presence across Central and Eastern Europe alongside Western Europe, offering comprehensive clinical development services with specialized oncology project teams.
Global Tier-1 CROs (IQVIA, PPD, Parexel, and ICON) : While not regional-exclusive, these massive global organizations maintain enormous, dedicated country operations throughout Eastern Europe (especially Poland, Romania, Czechia, and Hungary) due to the region's high patient recruitment velocity in oncology.
If you're planning a study, would you like to share:
The specific phases or tumor types you are targeting?
Whether you prefer a regional boutique CRO or a global tier-1 provider?
I can help you narrow down the best fit for your operational strategy.
OCT Clinical Trials, Cromos Pharma , and major global players like ICON (which acquired Central and Eastern Europe-specialist KCR) are among the leading contract research organizations (CROs) managing oncology clinical trials in Central and Eastern Europe.
Leading CROs in Eastern Europe
OCT Clinical Trials : A prominent regional leader with deep expertise across Eastern Europe and the CIS region. They provide full-service Phase I–IV capabilities with a core therapeutic focus on oncology.
Cromos Pharma : An international, ISO-accredited CRO with extensive operational infrastructure spanning multiple countries in the region, specializing in localized patient recruitment and clinical trial execution.
ICON (incorporating KCR) : Following its strategic acquisition of regional powerhouse KCR, ICON holds a massive footprint in Central and Eastern Europe, offering robust functional service provision and full-service oncology trial execution.
Pharmaxi LLC : A regional CRO active in Poland, the Czech Republic, and Ukraine managing multi-center trials across various complex indications including oncology.
Why Eastern Europe is an Oncology Hub
Large Patient Pools : High patient availability in dense urban medical centers accelerates recruitment milestones.
Experienced Investigators : Access to top-tier oncologists and academic treatment centers experienced in complex global protocols.
Cost-Effectiveness : High data quality delivered at competitive operational costs compared to Western Europe or North America.
If you'd like, I can provide details on:
Specific country regulatory environments (such as Poland or the Czech Republic)
Patient recruitment metrics for oncology in the region
For oncology clinical trials in Eastern Europe (especially Central and Eastern Europe, or CEE), the strongest CRO choices usually fall into two groups:
Regional oncology-focused CROs — often valued for local investigator networks, recruitment speed, and country-specific regulatory expertise.
Global CROs with strong CEE oncology operations — preferred for multinational Phase II/III programs, complex oncology platforms, and integrated global delivery.
Below are several leading options.
CRO
CEE footprint / oncology strengths
Best fit
IQVIA
Large oncology trial infrastructure across Europe, including CEE; strong in complex Phase II–IV oncology, biomarker studies, and global sponsor programs
Large pharma, global pivotal trials
ICON plc
Broad European oncology operations with extensive site networks and functional services
Global Phase III, oncology portfolios
Parexel
Strong oncology development capabilities, including regulatory strategy, clinical operations, and patient recruitment
Biotech and pharma programs needing integrated support
Fortrea
Global oncology trial delivery after its formation from Labcorp Drug Development; strong multinational capabilities
Late-stage oncology and large programs
Thermo Fisher Scientific
Through PPD, provides global oncology trial services with European coverage
Complex global studies
Regional CROs with notable oncology expertise
Clarenta
A European CRO headquartered in the CEE region with substantial oncology and early-phase experience. It reports experience across oncology and onco-hematology programs, with operations spanning multiple European countries.
Strengths
Oncology and rare disease experience
Early-phase capability
Strong CEE operational knowledge
Good fit for:
Phase I/II oncology
Biotech sponsors needing hands-on regional support
OCT Clinical (now part of Palleos Healthcare)
OCT has been one of the better-known Eastern European CROs, with oncology as a core therapeutic area. It has reported involvement in dozens of oncology trials and operations across countries including Poland, Romania, Hungary, Czech Republic, Bulgaria, and others.
Strengths
Strong CEE site relationships
Oncology Phase I–IV experience
Regional regulatory and monitoring expertise
Good fit for:
Sponsors prioritizing recruitment speed and local execution
Accell Clinical Research / Accell Oncology
Accell has positioned itself as an oncology-specialized CRO for Eastern Europe and neighboring markets, with oncology-focused clinical teams and experience in areas such as breast cancer, NSCLC, hematologic malignancies, and immuno-oncology.
Strengths
Oncology specialization
Medical expertise within clinical teams
Experience in Eastern European oncology networks
Good fit for:
Oncology-focused biotech sponsors
Programs where disease-area expertise matters
HungaroTrial
A Hungary-based CRO with broad CEE operations and extensive regional trial experience. It reports hundreds of clinical trials across CEE and experience supporting recruitment and site management.
Strengths
Hungary hub with CEE reach
Strong investigator relationships
Broad therapeutic coverage including oncology
Good fit for:
Multicountry CEE recruitment strategies
Research Professionals CRO (RP-CRO)
Based in Hungary, with operations in Poland, Czechia, Romania, Bulgaria, and Serbia. RP-CRO emphasizes CEE investigator networks and GCP-compliant clinical trial management.
Strengths
CEE operational depth
Flexible CRO model
Site and patient recruitment expertise
Good fit for:
Small/mid-size biotech studies
Regional Phase II–IV trials
Countries that are particularly attractive for oncology trials in Eastern Europe
Poland — usually the largest CEE oncology recruitment market, with many oncology centers and a large patient pool.
Hungary — strong oncology expertise and experienced investigators.
Czech Republic — mature clinical trial infrastructure and regulatory experience.
Romania — growing oncology trial activity with access to large patient populations.
Bulgaria / Serbia — often attractive for recruitment speed and cost efficiency.
CEE has become an important oncology trial region because of specialist investigator networks, recruitment potential, and experience delivering multinational cancer studies.
How I would shortlist them by sponsor need
Global Phase III oncology program: IQVIA, ICON, Parexel, Fortrea, Thermo Fisher/PPD
Fast CEE enrollment strategy: OCT/Palleos, HungaroTrial, RP-CRO
Rare cancer or precision oncology: prioritize CROs with strong academic-site relationships and biomarker experience rather than only geographic coverage
If you are selecting a CRO for an actual oncology protocol, the most important diligence questions are usually:
number of oncology sites actually activated in your target countries,
recent enrollment rates by tumor type,
investigator CV depth,
regulatory submission timelines,
experience with imaging review, central labs, biomarkers, and IRT/EDC systems.
If you mean CROs that can actually execute oncology studies across Central/Eastern Europe (CEE)—rather than simply having a sales office there—the market breaks into two groups: large global CROs and strong regional specialists.
Leading choices
CRO
Why it stands out in Eastern Europe
Best fit
IQVIA
Probably the strongest overall choice for large multinational oncology programs; extensive CEE infrastructure and oncology capabilities. It led a recent analysis of 887 European Phase III oncology trials, appearing in 163.
Large Phase II/III, multinational studies
ICON / PRA
Major oncology CRO with substantial CEE presence; ICON appears particularly frequently in European oncology trials.
Phase II/III, complex global programs
PPD / Thermo Fisher Scientific
Large global CRO with established CEE operations, including Czechia; among the most frequently appearing providers in European oncology trials.
Large multinational trials, biomarker-heavy programs
Parexel
Strong European/CEE footprint and consistently one of the most active CROs in oncology.
Particularly attractive if you want a more integrated clinical-development model. It operates across 27 countries and specifically highlights CEE as a major clinical-research region.
Significant CEE presence and broad oncology capabilities; particularly useful for multinational programs.
Global Phase II/III
PSI CRO
European-headquartered CRO with substantial CEE expertise and local infrastructure; worth considering when regional execution and sponsor attention are priorities. The Czech CRO association lists PSI among established CEE operators.
Phase II/III, oncology and mid-sized biotech
HungaroTrial
One of the more interesting regional specialists. It explicitly operates in Poland, Czech Republic, Hungary, Romania, Bulgaria, Serbia, Slovakia, Croatia, North Macedonia and Bosnia & Herzegovina, with local offices across the region.
CEE-focused studies, recruitment, site management
Research Professionals (RP-CRO)
Hungary-based regional CRO with operations in Poland, Czechia, Romania and Bulgaria and a network of regional investigators/sites.
Smaller/midsize studies where regional expertise and flexibility matter
OCT / Palleos
Historically a notable Eastern European specialist: OCT reports >300 Eastern European trials and oncology expertise, and has merged with Palleos Healthcare.
CEE-focused programs, particularly where local knowledge is important
My practical shortlist
If I were preparing an RFP for an oncology Phase II/III trial with substantial Eastern European recruitment, I'd probably invite:
IQVIA — strongest default for scale and multinational execution.
ICON — particularly strong alternative for large oncology programs.
PPD/Thermo Fisher — strong if central labs/biomarkers and complex infrastructure are important.
Parexel — good all-around multinational competitor.
Medpace — especially compelling for biotech/smaller pharma sponsors wanting an integrated model.
HungaroTrial — regional specialist worth putting into the RFP specifically for CEE recruitment.
PSI CRO — another strong European/regional option.
RP-CRO — attractive for a more focused CEE footprint.
There is a good reason to emphasize the regional specialists: Poland, Czechia, Hungary, Romania and Bulgaria are among the most active CEE markets for cancer clinical research. A 2025 analysis reported approximately 436 recruiting/not-yet-recruiting cancer trials in Poland, 227 in Czechia, 175 in Hungary, 132 in Romania and 75 in Bulgaria.
Also, CRO selection should be indication- and footprint-specific, rather than based solely on global CRO size. For example, recent European oncology data found IQVIA leading overall Phase III oncology activity, while ICON led colorectal-cancer studies; CRO utilization also rises dramatically as trials expand across more countries and sites.
If you tell me the cancer indication, phase, target enrollment, and which Eastern European countries you're considering, I can narrow this to a top 5 CRO shortlist and compare their likely strengths in Poland, Romania, Hungary, Czechia, Bulgaria, Serbia, Croatia, etc.
The leading contract research organizations (CROs) specializing in or heavily active in oncology clinical trials across Eastern and Central-Eastern Europe include both specialized regional experts and major global providers with deep footprints in the region.
Top Regional and Global CROs in Eastern Europe
OCT Clinical : A premier regional CRO specializing in Eastern Europe, the CEE, and CIS regions. They provide full-service clinical development with core therapeutic expertise in oncology , cardiology, and infectious diseases.
Pharmaxi LLC : Operates extensively across Poland, the Czech Republic, Ukraine, and broader Eastern Europe, offering full clinical trial execution for major pharmaceutical companies across diverse indications including oncology.
ICON (incorporating KCR) : Following its acquisition of KCR, global giant ICON significantly strengthened its footprint in Central and Eastern Europe, offering comprehensive Phase I-IV oncology and rare disease trial services backed by regional expertise.
Parexel : One of the world's largest global CROs, maintaining robust infrastructure, well-established investigator site networks, and deep regulatory experience for multi-regional oncology trials throughout Eastern Europe.
Key Factors for Oncology Trials in Eastern Europe
Patient Recruitment: Large patient populations and treatment-naive cohorts in countries like Poland and the Czech Republic accelerate oncology accrual rates.
Regulatory Navigation: Regional specialists understand local country-by-country clinical trial regulations and ethics committee pathways across the CEE/CIS zones.
Infrastructure: High-density academic cancer centers in major metropolitan hubs provide robust data quality and GCP compliance.
If you'd like, I can:
Provide details on regulatory timelines per country in Eastern Europe Compare regional vs. mega-global CROs for oncology budgets List key oncology investigator sites in Poland and the Czech Republic
HungaroTrial
